HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites

The impact of highly active antiretroviral therapy (HAART) in the natural history of AIDS disease has been allowed to prolong the survival of people with HIV infection, particularly whose with increased HIV viral load. Additionally, the antiretroviral therapy could exert a certain degree of protection against parasitic diseases. A number of studies have been evidenced a decrease in the incidence of opportunistic parasitic infections in the era of HAART. Although these changes have been attributed to the restoration of cell-mediated immunity, induced by either non-nucleoside reverse transcriptase inhibitors or HIV protease inhibitors, in combination with at least two nucleoside reverse transcriptase inhibitors included in HAART, there are evidence that the control of these parasitic infections in HIV-positive persons under HAART, is also induced by the inhibition of the proteases of the parasites. This review focuses on the principal available data related with therapeutic HIV-protease inhibitors and their in vitro and in vivo effects on the opportunistic protozoan parasites.

• Publication year

  2011

• Venue

  Open Medicinal Chemistry Journal

• Publication date

  2011-03-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1874104501105010040PMID 21629510PMCID 3103880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nelfinavir

  2012cited by this paper
• Lopinavir/Ritonavir

  2012cited by this paper
• Nelfinavir

  2012cited by this paper
• Darunavir

  2012cited by this paper
• Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010

  2011cited by this paper
• Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

  2010influential reference
• HIV Aspartyl Peptidase Inhibitors Interfere with Cellular Proliferation, Ultrastructure and Macrophage Infection of Leishmania amazonensis

  2009influential reference
• HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

  2009cited by this paper
• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  2009influential reference
• Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

  2009cited by this paper
• HIV protease inhibitors: recent clinical trials and recommendations on use

  2009influential reference
• Pharmacokinetic enhancers for HIV drugs.

  2009cited by this paper
• Synergy of Human Immunodeficiency Virus Protease Inhibitors with Chloroquine against Plasmodium falciparum In Vitro and Plasmodium chabaudi In Vivo

  2008cited by this paper
• Role of atazanavir in the treatment of HIV infection

  2008influential reference
• Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007

  2008cited by this paper
• Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

  2008cited by this paper
• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  2008cited by this paper
• Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

  2008cited by this paper
• A Family of Aspartic Proteases and a Novel, Dynamic and Cell‐Cycle‐Dependent Protease Localization in the Secretory Pathway of Toxoplasma gondii

  2007cited by this paper
• Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings

  2007cited by this paper
• Proteinase inhibitors and helminth parasite infection

  2007cited by this paper
• Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections

  2007cited by this paper
• The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis.

  2007cited by this paper
• HIV and malaria: interactions and implications

  2007cited by this paper
• Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients

  2007cited by this paper
• Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

  2007cited by this paper
• A review of nelfinavir for the treatment of HIV infection

  2006cited by this paper
• Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system

  2006cited by this paper
• Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro

  2006cited by this paper
• An Update and Review of Antiretroviral Therapy

  2006influential reference
• No Virological Failure in Semen During Properly Suppressive Antiretroviral Therapy Despite Subtherapeutic Local Drug Concentrations

  2006cited by this paper
• Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria

  2006cited by this paper
• Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

  2006cited by this paper
• The impact of HIV-protease inhibitors on opportunistic parasites.

  2005cited by this paper
• Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.

  2005cited by this paper
• Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors

  2005cited by this paper
• Nelfinavir: a review of its use in the management of HIV infection.

  2005cited by this paper
• Switching to Atazanavir Improves Metabolic Disorders in Antiretroviral-Experienced Patients With Severe Hyperlipidemia

  2005cited by this paper
• Antileishmanial activity of HIV protease inhibitors.

  2005cited by this paper
• HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa

  2004cited by this paper
• Tolerability and Safety of HIV Protease Inhibitors in Adults

  2004cited by this paper
• The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women

  2004cited by this paper
• Cysteine peptidases as virulence factors of Leishmania.

  2004cited by this paper
• Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.

  2004cited by this paper
• [Highly Active AntiRetroviral Therapy and cryptosporidiosis].

  2004influential reference
• Antiretrovirals as antimalarial agents.

  2004cited by this paper
• Toxoplasmosis

  2004cited by this paper
• Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity

  2003cited by this paper
• Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes.

  2003cited by this paper
• New Anti-HIV Protease Inhibitors Provide More Treatment Options

  2003cited by this paper
• Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite.

  2003cited by this paper
• Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.

  2003influential reference
• HIV-1, antiretroviral therapy, and malaria.

  2003cited by this paper
• Aspartic Peptidase Inhibitors: Implications in Drug Development

  2003cited by this paper
• Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis

  2003cited by this paper
• Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.

  2003cited by this paper
• Leishmania/HIV co-infections: epidemiology in Europe

  2003influential reference
• The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function.

  2003cited by this paper
• Efficacy of antigiardial drugs

  2003cited by this paper
• Toxoplasma gondii: transmission, diagnosis and prevention.

  2002cited by this paper
• Structure and mechanism of the pepsin-like family of aspartic peptidases.

  2002cited by this paper
• Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine

  2002cited by this paper
• Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

  2002cited by this paper
• Indinavir Crystallization Around the Loop of Henle: Experimental Evidence

  2001cited by this paper
• Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.

  2001cited by this paper
• Pharmacology and clinical experience with saquinavir

  2001influential reference
• Aspartyl proteinase genes from apicomplexan parasites: evidence for evolution of the gene structure.

  2001cited by this paper
• Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

  2001cited by this paper
• A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.

  2001cited by this paper
• An immunoassay for the measurement of sirolimus.

  2000cited by this paper
• Effect of Antiretroviral Therapy on Cryptosporidiosis and Microsporidiosis in Patients Infected with Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Amprenavir

  2000cited by this paper
• Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy

  2000cited by this paper
• Panel on Clinical Practices for Treatment of HIV Infection

  2000cited by this paper
• Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.

  2000cited by this paper
• 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

  2000cited by this paper
• Central nervous system toxoplasmosis in HIV pathogenesis, diagnosis, and therapy

  2000cited by this paper
• Amprenavir: a review of its clinical potential in patients with HIV infection.

  2000cited by this paper
• Anti-Toxoplasma Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro

  2000cited by this paper
• Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel.

  1999cited by this paper
• The Leishmania mexicana proteasome.

  1999cited by this paper
• A Role for Host Phosphoinositide 3-Kinase and Cytoskeletal Remodeling during Cryptosporidium parvumInfection

  1999cited by this paper
• Proteases of protozoan parasites.

  1999cited by this paper
• Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population.

  1999cited by this paper
• Saquinavir

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Ritonavir

  1998cited by this paper
• Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.

  1998cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• HIV-protease inhibitors.

  1998cited by this paper
• HIV-1 protease inhibitors.

  1997cited by this paper
• HIV-1 protease inhibitors. A review for clinicians.

  1997cited by this paper
• Antagonistic effect of human alpha-1-antitrypsin on excystation of Cryptosporidium parvum oocysts.

  1997cited by this paper
• HIV-1 protease inhibitors. A review for clinicians.

  1997cited by this paper
• Protease activity associated with excystation of Cryptosporidium parvum oocysts.

  1996cited by this paper
• HIV protease inhibitors

  1996influential reference
• Giardiasis.

  1996cited by this paper
• Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell culture system.

  1996cited by this paper
• Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.

  1995cited by this paper
• HIV-1 protease inhibitors

  1992cited by this paper

• Therapeutic potential of spiramycin-nanoparticles and Aluvia in experimental congenital toxoplasmosis.

  2025cites this paper
• Associations Between Antiprotozoal Treatments and Reduced Mortality Across Populations Suggest That Protozoal Colonization May Contribute Significantly to Human Mortality and Age-Related Morbidity

  2025cites this paper
• HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein

  2022cites this paper
• Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors

  2022cites this paper
• Cryptosporidium species in HIV patients in Alexandria, Egypt: distribution and associated clinical findings.

  2022cites this paper
• The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death.

  2021cites this paper
• Lopinavir and Nelfinavir Induce the Accumulation of Crystalloid Lipid Inclusions within the Reservosomes of Trypanosoma cruzi and Inhibit Both Aspartyl-Type Peptidase and Cruzipain Activities Detected in These Crucial Organelles

  2021cites this paper
• In vitro susceptibility of human Blastocystis subtypes to simeprevir

  2021cites this paper
• Disseminated microsporidiosis: An underdiagnosed and emerging opportunistic disease.

  2021cites this paper
• Comparison of Trichomoniasis Diagnosis by Microscopic Methods and Indirect ELISA Technique in a Sample of Iraqi Women

  2020cites this paper
• Intestinal parasites among HIV/AIDS patients attending University of Gondar Hospital, northwest Ethiopia

  2019cites this paper
• Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.

  2019cites this paper
• Preliminary Results Indicate the Anti-Proliferative Effect of HIV-1 Protease Inhibitors on Trypanosoma brucei Cells can be Due to the Non-Specific Targeting of Metallo-and Cysteine-Proteases

  2019cites this paper
• Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation

  2018cites this paper
• Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms.

  2018cites this paper
• Asymmetric peptidomimetics containing L-tartaric acid core inhibit the aspartyl peptidase activity and growth of Leishmania amazonensis promastigotes

  2018influential citation
• Efecto in vitro del antirretroviral tipranavir sobre taquizoitos de Toxoplasma gondii

  2018cites this paper
• IDENTIFICATION OF POTENTIAL TARGETS FOR RETROVIRAL PROTEASE INHIBITORS IN Plasmodium berghei

  2018cites this paper
• Deciphering the effects of nelfinavir and lopinavir on epimastigote forms of Trypanosoma cruzi.

  2017cites this paper
• The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi.

  2017cites this paper
• HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi.

  2016cites this paper
• Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity.

  2016cites this paper
• Modulation of cyptosporidiosis by CD4 levels in chronic diarrhoea HIV/AIDS individuals visiting Tarkwa Municipal hospital, Ghana

  2016cites this paper
• PREVALENCE OF INTESTINAL PARASITIC INFECTIONS IN HIV INFECTED PATIENTS PRESENTING WITH DIARRHEA AND THEIR ASSOCIATION WITH CD4+ COUNTS

  2015cites this paper
• Understanding drug resistance in human intestinal protozoa

  2015cites this paper
• EVALUATION OF INTESTINAL PARASITE INFECTIONS IN HIV/AIDS PATIENTS ON ANTIRETROVIRAL THERAPY (ART) IN SELECTED HIV CLINICS IN CAPE COAST METROPOLIS.

  2015cites this paper
• Prevalence of Intestinal Parasites and Other Parasites among HIV/AIDS Patients with on-ART Attending Dilla Referral Hospital, Ethiopia

  2014cites this paper
• Prevalence of intestinal parasites among HIV patients at the Yaoundé Central Hospital, Cameroon

  2014cites this paper
• Molecular modeling studies and comparative analysis on structurally similar HTLV and HIV protease using HIV-PR inhibitors

  2014influential citation
• Long Chain Fatty Acyl-Coenzyme A Synthetase as Novel Drug Targets in Cryptosporidium parvum

  2014cites this paper
• Prevalence of intestinal parasites and associated risk factors among HIV/AIDS patients with pre-ART and on-ART attending dessie hospital ART clinic, Northeast Ethiopia

  2013cites this paper
• Transition State Analogues of Enzymatic Reaction as Potential Drugs

  2013cites this paper
• The impact of helminth infection in patients with active tuberculosis

  2013cites this paper
• New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases.

  2013cites this paper
• HIV treatments have malaria gametocyte killing and transmission blocking activity.

  2013cites this paper
• HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals.

  2013cites this paper
• Prevalence of opportunistic intestinal parasite infection in HIV positive population of central India region

  2013cites this paper
• Intestinal parasitic and candida infection associated with HIV infection in Cameroon.

  2013cites this paper
• In silico screening of indinavir-based compounds targeting proteolytic activity in HIV PR: binding pocket fit approach

  2012cites this paper
• Perfil epidemiológico de portadores do HIV com manifestações estomatológicas em cinco centros de referência na cidade de Porto Alegre

  2012cites this paper
• Impact of L38↑N↑L insertions on structure and function of HIV-1 South African subtype C Protease

  2012cites this paper
• Pharmacophore modeling and 3D QSAR combined with virtual screening to identify novel inhibitors of protein targets of infectious diseases

  2010cites this paper